Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does INFLIXIMAB Cause Upper respiratory tract infection? 1,223 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 1,223 reports of Upper respiratory tract infection have been filed in association with INFLIXIMAB (Renflexis). This represents 0.9% of all adverse event reports for INFLIXIMAB.

1,223
Reports of Upper respiratory tract infection with INFLIXIMAB
0.9%
of all INFLIXIMAB reports
336
Deaths
276
Hospitalizations

How Dangerous Is Upper respiratory tract infection From INFLIXIMAB?

Of the 1,223 reports, 336 (27.5%) resulted in death, 276 (22.6%) required hospitalization, and 140 (11.4%) were considered life-threatening.

Is Upper respiratory tract infection Listed in the Official Label?

Yes, Upper respiratory tract infection is listed as a known adverse reaction in the official FDA drug label for INFLIXIMAB.

What Other Side Effects Does INFLIXIMAB Cause?

Off label use (34,801) Drug ineffective (33,738) Condition aggravated (16,616) Rheumatoid arthritis (16,251) Pain (15,061) Fatigue (13,473) Arthralgia (13,441) Infusion related reaction (12,946) Product use issue (12,752) Drug intolerance (11,173)

What Other Drugs Cause Upper respiratory tract infection?

ADALIMUMAB (3,306) ETANERCEPT (2,948) TOFACITINIB (1,805) RITUXIMAB (1,713) ABATACEPT (1,623) METHOTREXATE (1,576) TOCILIZUMAB (1,455) APREMILAST (1,437) PREDNISONE (1,354) SECUKINUMAB (1,339)

Which INFLIXIMAB Alternatives Have Lower Upper respiratory tract infection Risk?

INFLIXIMAB vs INFLIXIMAB-ABDA INFLIXIMAB vs INFLIXIMAB-AXXQ INFLIXIMAB vs INFLIXIMAB-DYYB INFLIXIMAB vs INFLIXIMAB-QBTX INFLIXIMAB vs INFLIXIMAB, RECOMBINANT

Related Pages

INFLIXIMAB Full Profile All Upper respiratory tract infection Reports All Drugs Causing Upper respiratory tract infection INFLIXIMAB Demographics